SUVEN2023-10-012023-12-31 SUVEN2023-10-012023-12-31 SUVEN2023-10-012023-12-31in-bse-fin:OneOperatingExpenses01Member SUVEN2023-10-012023-12-31in-bse-fin:OneOperatingExpenses02Member SUVEN2023-10-012023-12-31in-bse-fin:FourOperatingExpenses01Member SUVEN2023-10-012023-12-31in-bse-fin:FourOperatingExpenses02Member SUVEN2023-12-31 iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares 530239 SUVEN NOTLISTED Suven Life Sciences Limited Equity 2023-04-01 2024-03-31 2024-01-30 2024-01-23 INR Lakhs Third quarter 11:30:00 12:45:00 2024-01-30 2024-01-30 Not applicable Single segment The Company has only one business segment, i.e. Research & Development and does not operate in any other segments. Hence, segment reporting as per IND AS 108 (Operating Segment) is not presented 2023-10-01 2023-12-31 Unaudited Consolidated 24508000.00 60656000.00 85164000.00 0.00 0.00 0.00 57937000.00 354000.00 16029000.00 428493000.00 502813000.00 -417649000.00 0.00 -417649000.00 0.00 0.00 0.00 0.00 -417649000.00 0.00 0.00 0.00 0.00 -417649000.00 475000.00 -417174000.00 0.00 0.00 0.00 0.00 218074000.00 1 -1.92 -1.92 0.00 0.00 -1.92 -1.92 Notes: 1)The above financial results of the Company has been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on January 30, 2024. The results for the quarter ended December 31, 2023 has been reviewed by our statutory auditors. 2)The above financial results have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) as amended, prescribed under Section 133 of the Companies Act, 2013, read with relevant rules issued thereunder. 3)The consolidated financial results include the results of the wholly Owned Subsidiary, Suven Neurosciences , Inc . 4)The Company has only one business segment, i.e. Research & Development and does not operate in any other segments. Hence, segment reporting as per IND AS 108 (Operating Segment) is not presented. 5)The Company has alloted 72691239 equity shares amounting to Rs.39980.18 lakhs through rights issue on November 16,2022. Summary of Utilisation of Proceeds of Rights issue: Particulars Amount Rs.In lakhs Amout Raised through Rights Issue of Shares 39980.18 Less: Rights Issue Expenses 280.00 Less: Amount Utilised 21276.20 Balance Amount 18423.98 6)Pursuant to a fire accident on April 26, 2020 at Jeedimetla Plant, certain fixed assets and other materials in the effected buildings were damaged. The insurance claim was settled and the Company has received total payment from the Insurnace Company of Rs.19.45 Crores (including the final payment of Rs.7.45 Crores received during the second quarter of FY 2023-24). 7) The corresponding previous period figures have been regrouped / reclassified where ever necessary. Single segment 2023-04-01 2023-12-31 Unaudited Consolidated 93077000.00 168469000.00 261546000.00 0.00 0.00 0.00 155227000.00 1285000.00 49938000.00 915018000.00 1121468000.00 -859922000.00 74566000.00 -785356000.00 0.00 0.00 0.00 0.00 -785356000.00 0.00 0.00 0.00 0.00 -785356000.00 1424000.00 -783932000.00 0.00 0.00 0.00 0.00 218074000.00 1 -3.60 -3.60 0.00 0.00 -3.60 -3.60 Other Expenses 12274000.00 R & D Expenses 416219000.00 Other Expenses 45963000.00 R & D Expenses 869055000.00 475000.00 1424000.00 0.00 0.00 0.00 0.00